TP53 and acute myeloid leukemia: Our data provide novel insights into the mechanisms of CDK7 inhibition via CDK7/c-Myc/p53 axis that has not been reported previously in solid or liquid tumors and combined treatment with XL102 and Venetoclax led to synergistic effects in overcoming resistance to Venetoclax in AML.